Whats new in the treatment of cocaine addiction?

Current Psychiatry Reports

Volumn 12, Issue 5, 2010, Pages 441-447

  Kampman, Kyle M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cocaine; Contingency management; Pharmacotherapy; Relapse; Withdrawal

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; APREPITANT; BUPRENORPHINE; CITALOPRAM; COCAINE VACCINE; DESIPRAMINE; DISULFIRAM; DOPAMINE RECEPTOR BLOCKING AGENT; ECOPIPAM; MODAFINIL; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NALTREXONE; NEUROKININ 1 RECEPTOR ANTAGONIST; PLACEBO; TOPIRAMATE; UNCLASSIFIED DRUG; VACCINE; VIGABATRIN; DRUG DERIVATIVE; FRUCTOSE;

ABSTINENCE; ALCOHOLISM; AMPHETAMINE DEPENDENCE; BEHAVIOR THERAPY; CLINICAL TRIAL; COCAINE DEPENDENCE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EUPHORIA; GABAERGIC TRANSMISSION; HUMAN; NARCOLEPSY; NONHUMAN; OPIATE ADDICTION; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; VOUCHER BASED REINFORCEMENT THERAPY; WITHDRAWAL SYNDROME; CLINICAL TRIAL (TOPIC); UNITED STATES;

BEHAVIOR THERAPY; CLINICAL TRIALS AS TOPIC; COCAINE-RELATED DISORDERS; FRUCTOSE; HUMANS; UNITED STATES;

EID: 77958184624     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0143-5     Document Type: Review

References (50)

1. Substance Abuse and Mental Health Services Administration: Treatment Episode Data Set (TEDS): 1994-2004. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006.
2. Ball JK, Albright V: Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits. In Substance Abuse and Mental Health Services Administration (SAMHSA), (OAS) OoAS. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2007:8.
3. K Caroll 2004 Behavioral therapies for co-occurring substance use and mood disorders Biol Psychiatry 56 778 784 10.1016/j.biopsych.2004.07.010 (Pubitemid 39539836)
4. M Touret M Sallanon-Moulin C Fages, et al. 1994 Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain Brain Res Mol Brain Res 26 123 128 1:CAS:528:DyaK2cXmslWqsr8%3D 10.1016/0169-328X(94)90082-5 7854038 (Pubitemid 24311032)
5. C Dackis CP OBrien 2003 Glutamatergic agents for cocaine dependence Ann N Y Acad Sci 1003 328 345 1:CAS:528:DC%2BD2cXptlGqug%3D%3D 10.1196/annals.1300. 021 14684456 (Pubitemid 38083066)
6. R Malcolm K Swayngim JL Donovan, et al. 2006 Modafinil and cocaine interactions Am J Drug Alcohol Abuse 32 577 587 10.1080/00952990600920425 17127546 (Pubitemid 44870996)
7. CA Dackis KG Lynch E Yu, et al. 2003 Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study Drug Alcohol Depend 70 29 37 1:CAS:528:DC%2BD3sXis12rtrY%3D 10.1016/S0376-8716(02)00335-6 12681523 (Pubitemid 36385151)
8. CL Hart M Haney SK Vosburg, et al. 2008 Smoked cocaine self-administration is decreased by modafinil Neuropsychopharmacology 3 761 768 10.1038/sj.npp.1301472 In this human laboratory trial, modafinil pretreatment reduced the subjective effects of cocaine and cocaine self-administration among cocaine-dependent individuals (Pubitemid 351252706)
9. C Dackis K Kampman K Lynch, et al. 2005 A double-blind, placebo-controlled trial of modafinil for cocaine dependence Neuropsychopharmacology 30 205 211 1:CAS:528:DC%2BD2cXhtVyisbjI 10.1038/sj.npp.1300600 15525998 (Pubitemid 40024415)
10. AL Anderson MS Reid SH Li, et al. 2009 Modafinil for the treatment of cocaine dependence Drug Alcohol Depend 104 133 139 1:CAS:528: DC%2BD1MXosleiu7g%3D 10.1016/j.drugalcdep.2009.04.015 19560290 This is the most recent and largest clinical trial of modafinil for the treatment of cocaine dependence. The results of this trial suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine nonuse days in participants without comorbid alcohol dependence, and was effective in reducing cocaine craving
11. Dworkin SI, Smith JE: Neurobehavioral pharmacology of cocaine. In Mechanisms of Cocaine Abuse and Toxicity. Edited by Clouet D, Ashgar K, Brown R. National Institute on Drug Abuse Research Monograph #88. Washington, DC: US Government Printing Office; 1988:185-198.
12. SL Dewey CS Chaurasia C Chen, et al. 1997 GABAergic attenuation of cocaine-induced dopamine release and locomoter activity Synapse 25 393 398 1:CAS:528:DyaK2sXisVKqurs%3D 10.1002/(SICI)1098-2396(199704)25:4<393::AID- SYN11>3.0.CO;2-W 9097399 (Pubitemid 27155151)
13. MR Gerasimov CR Ashby EL Gardner, et al. 1999 Gamma-vinyl-GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine Synapse 34 11 19 1:CAS:528:DyaK1MXls12kurc%3D 10.1002/(SICI)1098- 2396(199910)34:1<11::AID-SYN2>3.0.CO;2-5 10459167 (Pubitemid 29420291)
14. B Schmitz T Schmidt B Jokiel, et al. 2002 Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study J Neurol 249 469 475 1:STN:280:DC%2BD383ivFyrsw%3D%3D 10.1007/s004150200041 11967655 (Pubitemid 34304624)
15. K Manuchehri S Goodman L Siviter S Nightingale 2000 A controlled study of vigabatrin and visual abnormalities Br J Ophthalmol 84 499 505 1:STN:280:DC%2BD3c3ksFegtQ%3D%3D 10.1136/bjo.84.5.499 10781514 (Pubitemid 30251711)
16. JD Brodie E Figueroa SL Dewey, et al. 2003 Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA Synapse 50 261 265 1:CAS:528:DC%2BD3sXosleks7k%3D 10.1002/syn.10278 14515344 (Pubitemid 37315356)
17. JD Brodie E Figueroa EM Laska, et al. 2005 Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction Synapse 55 122 125 1:CAS:528:DC%2BD2cXhtFGmtLvO 10.1002/syn.20097 15543630 (Pubitemid 39665670)
18. JD Brodie BG Case E Figueroa, et al. 2009 Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees Am J Psychiatry 166 1269 1277 10.1176/appi.ajp.2009.08121811 19651710 This was the first double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence. In this trial, full end-of-trial abstinence was achieved in 14 vigbatrin-treated individuals (28.0%) compared with four in the placebo arm (7.5%). Twelve participants in the vigabatrin group and two in the placebo group maintained abstinence through the follow-up period
19. OA Petroff F Hyder RH Mattson DL Rothman 1999 Topiramate increases brain GABA, homocarnasine, and pyrrolidinone in patients with epilepsy Neurology 52 473 478 1:CAS:528:DyaK1MXhtlShsr0%3D 10025774
20. J Gibbs S Sombati R DeLorenzo D Coulter 2000 Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons Epilepsia 41 Suppl 1 S10 S16 1:CAS:528:DC%2BD3cXivFWktrk%3D 10.1111/j.1528-1157.2000.tb02164.x 10768293
21. JL Cornish PW Kalivas 2000 Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction J Neurosci 20 1 5
22. KM Kampman H Pettinati K Lynch, et al. 2004 A pilot trial of topiramate for the treatment of cocaine dependence Drug Alcohol Depend 75 233 240 1:CAS:528:DC%2BD2cXmt1Wksbk%3D 10.1016/j.drugalcdep.2004.03.008 15283944 (Pubitemid 38993293)
23. F Hameedi M Rosen E McCance-Katz, et al. 1995 Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans Biol Psychiatry 37 560 563 1:CAS:528:DyaK2MXmtFWmsbk%3D 10.1016/0006-3223(94)00361-6 7619981
24. K Caroll L Fenton S Ball, et al. 2004 Efficacy of disulfiram and cognitive behavioral therapy in cocaine dependent outpatients: a randomized placebo-controlled trial Arch Gen Psychiatry 61 264 272 10.1001/archpsyc.61.3. 264 (Pubitemid 38295828)
25. K Caroll C Nich S Ball, et al. 1998 Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram Addiction 93 713 727 10.1046/j.1360-0443.1998.9357137.x
26. T George M Chawarski J Pakes, et al. 2000 Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial Biol Psychiatry 47 1080 1086 1:CAS:528:DC%2BD3cXktV2qsr0%3D 10.1016/S0006- 3223(99)00310-8 10862808 (Pubitemid 30336217)
27. I Petrakis K Caroll C Nich, et al. 2000 Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts Addiction 95 219 228 1:STN:280:DC%2BD3c7ovV2htw%3D%3D 10.1046/j.1360-0443.2000.9522198.x 10723850
28. HM Pettinati KM Kampman KG Lynch, et al. 2008 A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence Addict Behav 33 651 667 10.1016/j.addbeh.2007.11.011 18079068 In this trial, naltrexone, disulfiram, and the combination of these medications were compared with placebo for the treatment of cocaine and alcohol dependence. In the primary analyses (generalized estimating equation modeling), abstinence from cocaine as measured by cocaine-negative urines and days of self-reported abstinence from cocaine or alcohol did not differ between placebo and any of the medication groups. However, patients taking disulfiram (alone or in combination) were most likely to achieve combined abstinence from cocaine and alcohol. Secondary analyses revealed that patients taking the disulfiram-naltrexone combination were most likely to achieve 3 consecutive weeks of abstinence from cocaine and alcohol
29. K Kantak S Collins E Lipman, et al. 2000 Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model Psychopharmacology (Berl) 148 251 262 1:CAS:528:DC%2BD3cXit1ensb4%3D 10.1007/s002130050049
30. T Kosten M Rosen J Bond, et al. 2002 Human therapeutic cocaine vaccine: safety and immunogenicity Vaccine 20 1196 1204 1:CAS:528:DC%2BD38Xms1ejtw%3D%3D 10.1016/S0264-410X(01)00425-X 11803082 (Pubitemid 34135957)
31. B Martell E Mitchell J Poling, et al. 2005 Vaccine pharmacotherapy for the treatment of cocaine dependence Biol Psychiatry 58 158 164 1:CAS:528:DC%2BD2MXmsVWrsLs%3D 10.1016/j.biopsych.2005.04.032 16038686 (Pubitemid 41008133)
32. BA Martell FM Orson J Poling, et al. 2009 Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial Arch Gen Psychiatry 66 1116 1123 1:CAS:528:DC%2BD1MXhtleiurnM 10.1001/archgenpsychiatry.2009.128 19805702 In this trial, 115 cocaine-dependent patients were randomly assigned to receive a vaccine that stimulated the production of anticocaine antibodies or placebo. The 21 vaccinated patients (38%) who attained serum IgG anticocaine antibody levels of 43 μg/mL or higher (i.e., high IgG level) had significantly more cocaine-free urine samples than those with levels less than 43 μg/mL (i.e., low IgG level) and the placebo-receiving patients during weeks 9 to 16 (45% vs. 35% cocaine-free urine samples, respectively). The proportion of patients having a 50% reduction in cocaine use was significantly greater in those with a high IgG level than in those with a low IgG level (53% vs. 23% of patients, respectively; P∈=∈0.048)
33. PW Mantyh SP Hunt JE Maggio 1984 Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand Brain Res 307 147 165 1:CAS:528:DyaL2cXls1ChsLs%3D 10.1016/0006-8993(84)90470-0 6087984
34. A Holmes M Heilig NMJ Rupniak, et al. 2003 Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.[see comment] Trends Pharmacol Sci 24 580 588 1:CAS:528:DC%2BD3sXos12ks7o%3D 10.1016/j.tips.2003.09. 011 14607081 (Pubitemid 37357142)
35. R Sinha M Garcia P Paliwal, et al. 2006 Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes Arch Gen Psychiatry 63 324 331 10.1001/archpsyc.63.3.324 16520439 (Pubitemid 43345357)
36. KM Kampman JR Volpicelli FD Mulvaney, et al. 2002 Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence Addict Behav 27 251 260 10.1016/S0306-4603(01)00171-X 11817766 (Pubitemid 34003038)
37. CA Heidbreder EL Gardner Z-X Xi, et al. 2005 The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence Brain Res Brain Res Rev 49 77 105 1:CAS:528:DC%2BD2MXlt1Ghu7k%3D 10.1016/j.brainresrev. 2004.12.033 15960988 (Pubitemid 40800164)
38. P Sokoloff J Diaz B Le Foll, et al. 2006 The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders CNS Neurol Disord Drug Targets 5 25 43 1:CAS:528:DC%2BD28XisFKns7o%3D 10.2174/ 187152706784111551 16613552
39. SR Vorel CR Ashby Jr M Paul, et al. 2002 Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats J Neurosci 22 9595 9603 1:CAS:528:DC%2BD3sXmsVGmtr8%3D 12417684
40. P Di Ciano RJ Underwood JJ Hagan BJ Everitt 2003 Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A Neuropsychopharmacology 28 329 338 10.1038/sj.npp.1300148 12589386
41. Z-X Xi AH Newman JG Gilbert, et al. 2006 The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaines rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats Neuropsychopharmacology 31 1393 1405 1:CAS:528:DC%2BD28Xls1Kitr4%3D 10.1038/sj.npp.1300912 16205781
42. Z-X Xi J Gilbert AC Campos, et al. 2004 Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats Psychopharmacology 176 57 65 1:CAS:528:DC%2BD2cXot1ait7c%3D 10.1007/s00213-004- 1858-y 15083257 (Pubitemid 39506367)
43. PW Kalivas ND Volkow 2005 The neural basis of addiction: a pathology of motivation and choice Am J Psychiatry 162 1403 1413 10.1176/appi.ajp.162.8.1403 16055761 (Pubitemid 41105554)
44. D Baker K McFarland R Lake, et al. 2003 N-acetyl cysteine-induced blockade of cocaine-induced reinstatement Ann N Y Acad Sci 1003 349 351 10.1196/annals.1300.023 14684458 (Pubitemid 38083068)
45. SD LaRowe H Myrick S Hedden, et al. 2007 Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 164 1115 1117 10.1176/appi.ajp.164.7.1115 17606664 In this double-blind, placebo-controlled trial, 15 participants received NAC or placebo during a 3-day hospitalization. Participants were crossed over to receive the opposite condition on a second, identical 3-day stay occurring 4 days later. During each hospital stay, participants completed a cue reactivity procedure that involved collecting psychophysical and subjective data in response to slides depicting cocaine and cocaine use. While taking NAC, participants reported less desire to use and less interest in response to cocaine slides and watched cocaine slides for less time. NAC may be useful in reducing cocaine craving (Pubitemid 47121401)
46. SD LaRowe P Mardikian R Malcolm, et al. 2006 Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals Am J Addict 15 105 110 10.1080/10550490500419169 16449100 (Pubitemid 43207196)
47. ST Higgins AJ Budney WK Bickel, et al. 1994 Incentives improve outcome in outpatient behavioral treatment of cocaine dependence Arch Gen Psychiatry 51 568 576 1:STN:280:DyaK2czgsVehsQ%3D%3D 8031230
48. T Kosten A Oliveto A Feingold, et al. 2003 Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients Drug Alcohol Depend 70 315 325 1:CAS:528:DC%2BD3sXjvV2lu74%3D 10.1016/S0376-8716(03)00032-2 12757969 (Pubitemid 36577343)
49. J Poling A Oliveto N Petry, et al. 2006 Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population Arch Gen Psychiatry 63 219 228 1:CAS:528:DC%2BD28XhslWku7k%3D 10.1001/archpsyc.63.2.219 16461866 (Pubitemid 43213884)
50. FG Moeller JM Schmitz JL Steinberg, et al. 2007 Citalopram combined with behavioral treatment reduces cocaine use: a double-blind, placebo-controlled trial Am J Drug Alcohol Abuse 33 367 378 10.1080/00952990701313686 17613964 The purpose of this study was to examine whether the SSRI citalopram would reduce cocaine-positive urines in a 12-week, double-blind, placebo-controlled trial. Seventy-six cocaine-dependent patients received citalopram, 20 mg/d, or placebo along with cognitive-behavioral therapy and contingency management. Citalopram-treated patients showed a significant reduction in cocaine-positive urines during treatment compared with placebo-treated patients (Pubitemid 47037175)